Strides
Pharma Science is currently trading at Rs. 381.30, up by 4.15 points or
1.10% from its previous closing of Rs. 377.15 on the BSE.
The
scrip opened at Rs. 379.20 and has touched a high and low of Rs. 382.75
and Rs. 375.50 respectively. So far 92906 shares were traded on the
counter.
The BSE group
'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 550.40
on 22-Jan-2019 and a 52 week low of Rs. 288.00 on 09-Oct-2019.
Last
one week high and low of the scrip stood at Rs. 394.85 and Rs. 375.10
respectively. The current market cap of the company is Rs. 3407.49
crore.
The promoters
holding in the company stood at 31.28%, while Institutions and
Non-Institutions held 46.45% and 22.27% respectively.
Strides
Pharma Science’s step‐down wholly owned subsidiary, Strides Pharma
Global Pte, Singapore, has received tentative approval for Diclofenac
Potassium Softgel Capsules, 25 mg from the United States Food & Drug
Administration (USFDA). The product is a generic version of Zipsor
Capsules, 25 mg, of Assertio Therapeutics, Inc. Diclofenac Potassium
Softgel Capsules is part of Strides niche and small volume product
portfolio with limited competition in the US market. According to IQVIA
MAT data, the US market for Diclofenac Potassium Softgel Capsules, 25 mg
is approximately $30 million.
The company has 102 cumulative ANDA filings with USFDA of which 67 ANDAs have been approved and 35 are pending approval.
Strides
Pharma Science (Formerly Strides Shasun) is a pharmaceutical company
with a major focus on development and manufacture of IP-led niche
finished dosage formulations. It is also among the world’s largest
manufacturers of soft gelatin capsules.
0 comments:
Post a Comment
Please add comment